What is Penumbra's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Penumbra year over year?

What were the key takeaways from Penumbra's earnings call?

Did Penumbra beat or miss consensus estimates last quarter?

What factors drove the changes in Penumbra's revenue and profit?

What is Penumbra's gross profit margin?

What were the key takeaways from Penumbra’s earnings call?

What does Penumbra do and what are its main business segments?

- **Revenue Growth**: Q3 2025 revenue up 17.8% YoY to $354.7M, driven by 34% VTE growth and 29.2% embolization/access expansion.
- **CAVT Innovation**: FDA clears Lightning Bolt 16 and Flash 3.0; STORM-PE trial validates CAVT superiority, spurring hospital protocol updates.
- **Margin Expansion**: Gross margin 67.8% (up 130bps YoY); targeting >70% by 2026. Operating income $48.8M (13.8% of revenue).
- **Guidance Update**: 2025 revenue raised to $1.375-$1.380B; U.S. thrombectomy growth 20-21%.
- **Pipeline Momentum**: Thunderbolt FDA review active; Flash 3.0 enhances case efficiency, Ruby XL stabilizes production.

**【CEO Summary Section】**
- Q3 2025 revenue reached $354.7 million, up 17.8% YoY, driven by 18.5% growth in U.S. thrombectomy and 29.2% in embolization/access. VTE franchise grew 34%, while U.S. embolization/access revenue rose 29.2%.
- FDA cleared Lightning Bolt 16 and Flash 3.0, enhancing CAVT portfolio for over 800,000 U.S. VTE patients. STORM-PE trial showed CAVT superior to anticoagulation alone, with faster recovery and safety profile.
- Gross margin expanded 130bps to 67.8%, targeting >70% by end-2026. Raised 2025 revenue guidance to $1.375-$1.380 billion, with U.S. thrombectomy growth of 20-21%.

**【CFO Financial Commentary】**
- Q3 GAAP revenue $354.7M, non-GAAP operating income $48.8M (13.8% of revenue). Gross margin 67.8%, up 180bps QoQ, driven by product and regional mix. Operating expenses $191.6M (54% of revenue), reflecting embolization team build-out.
- Adjusted EBITDA $66.7M (18.8% of revenue). Cash balance $470.3M, up $45.7M QoQ. Full-year guidance maintained for margin expansion.

**【Q&A Highlights】**
- **Thunderbolt Approval**: FDA review ongoing; no timeline provided, but team optimistic. Product launch readiness confirmed post-approval.
- **STORM-PE Impact**: Non-interventionalists updating protocols, accelerating CAVT adoption. Q4 and 2026 growth expected from procedural volume increase.
- **Margins**: Gross margin to expand >70% by 2026; operating expenses stabilize post-sales team build-out.
- **International Recovery**: China headwinds easing; rest-of-world growth 6.6% YoY. Focus on neurovascular innovation (e.g., Thunderbolt) to drive future growth.
- **Product Pipeline**: Lightning Flash 3.0 improves case times; Ruby XL stabilizes production, supporting margin accretion.

PEN

PEN fundamentals

You can ask Aime